Julie Papanek Grant - Feb 1, 2021 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Director
Signature
/s/ Julie Papanek Grant
Stock symbol
DAWN
Transactions as of
Feb 1, 2021
Transactions value $
$208,000
Form type
4
Date filed
6/2/2021, 08:52 PM
Next filing
May 26, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Conversion of derivative security +7.33M +225.78% 10.6M Jun 1, 2021 By Canaan XI, L.P. F1, F2
transaction DAWN Common Stock Conversion of derivative security +148K +1.4% 10.7M Jun 1, 2021 By Canaan XI, L.P. F2, F3
transaction DAWN Common Stock Purchase $208K +13K +0.12% $16.00 10.7M Jun 1, 2021 By Canaan XI, L.P. F2
holding DAWN Common Stock 465K Feb 1, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Series B Preferred Stock Award +148K 148K Feb 1, 2021 Common Stock 148K By Canaan XI, L.P. F2, F4, F5
transaction DAWN Stock Option (right to buy Common Stock) Award $0 +63K $0.00 63K May 26, 2021 Common Stock 63K $16.00 Direct F6, F7
transaction DAWN Series A Preferred Stock Conversion of derivative security $0 -7.33M -100% $0.00* 0 Jun 1, 2021 Common Stock 7.33M By Canaan XI, L.P. F1, F2
transaction DAWN Series B Preferred Stock Conversion of derivative security $0 -148K -100% $0.00* 0 Jun 1, 2021 Common Stock 148K By Canaan XI, L.P. F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares of the Issuer's Series A Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its firm commitment initial public offering (the "IPO") pursuant to a registration statement on Form S-1 (File No. 333-255754) under the Securities Act of 1933, as amended (the "Registration Statement"), and had no expiration date.
F2 Represents securities held by Canaan XI, L.P. ("Canaan LP"). The Reporting Person, as a non-managing member of Canaan LP's general partner, Canaan Partners XI LLC, disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein, if any.
F3 The shares of the Issuer's Series B Preferred Stock automatically converted on a one-for-one basis into shares of the Issuer's Common Stock on May 26, 2021 in connection with the closing of the Issuer's sale of its Common Stock in its IPO pursuant to the Registration Statement, and had no expiration date.
F4 The Reporting Person is reporting the purchase of these securities pursuant to Rule 16a-2(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of Series B Preferred Stock automatically converted into one share of Common Stock at the close of the Issuer's IPO and has no expiration date.
F5 The number of securities reported reflects the 1 to 2.325 stock split of the Issuer's Common Stock and convertible preferred stock that was effected on May 23, 2021.
F6 The Reporting Person is reporting the acquisition of these securities pursuant to Rule 16a-2(a) of the Exchange Act.
F7 The option vests as to 1/36th of the total shares on each monthly anniversary, beginning on June 23, 2021, subject to the Reporting Person's provision of service to the Issuer on each vesting date.